Search - tctmd.com

Displaying 81 - 93 of 93

Sort: Relevancy | Date

News Daily News

2 Estudios Avalan el Uso de Dispositivos liberadores de Paclitaxel en el Tratamiento de la Enfermedad Femoropoplítea

Caitlin E. Cox

April 05, 2013

News Conference News TCT 2012

ETAP Trial: Nitinol Stent Bests Angioplasty for Popliteal Artery Disease

November 18, 2012

Presentation TCT 2012

Role of DCB in SFA Intervention: Predictions Five Years into the Future

Presenter: Thomas Zeller

October 25, 2012

News Industry News

Nitinol Stent Performs Better Than Balloon Angioplasty Alone in Treating Lesions of the Popliteal Artery

October 24, 2012

Presentation TCT 2012

A Prospective, Randomized Trial of Nitinol Stents vs. Balloon Angioplasty in Obstructive Popliteal Lesions

Presenter: Thomas Zeller

October 24, 2012

Presentation TCT 2012

Debate III. Is Long-term Patency Following Tibial Intervention for Critical Limb Ischemia Necessary? Pro!

Presenter: Thomas Zeller

October 23, 2012

Presentation TCT 2012

After CTO Recanalization, What Is the Role of Drug-Eluting Devices, Covered Stents, Etc?

Presenter: Thomas Zeller

October 23, 2012

Presentation TCT 2012

Expanding the Borders: Endovascular Intervention for Common Femoral and Popliteal Disease

Presenter: Thomas Zeller

October 22, 2012

News Industry News

Medtronic Completes Enrollment in Landmark Study of IN.PACT Drug-Eluting Balloon in Peripheral Artery Disease

October 05, 2012

Presentation TCT 2012

One year clinical outcomes of MISAGO2 the large multicentre study with Misago the new self-expanding nitinol peripheral stent - final results

Presenter: Karl-Ludwig Schulte, Ivan Kralj, Frank Vermassen, Marc Sapoval, Ralf Langhoff, Stefan M?ller H?lsbeck, Jan H Peregrin, Michael ?kesson, Thomas Zeller, Wolfgang Ritter

January 03, 2012

News Industry News

Bayer HealthCare's Cotavance Drug Eluting Balloon With Paccocath Technology Reduced Five-Year Target Lesion Revascularization Rates

November 09, 2011

News Industry News

Bayer HealthCare's MEDRAD Interventional Business Announces Five-Year Data of Cotavance® Drug Eluting Balloon with Paccocath® Technology to be Presented at 2011 TCT

November 03, 2011

News Industry News

The PROTEUS™ Device Combines Balloon Angioplasty and Embolic Capture of Particles

September 08, 2011

Advertisement

2 Estudios Avalan el Uso de Dispositivos liberadores de Paclitaxel en el Tratamiento de la Enfermedad Femoropoplítea

ETAP Trial: Nitinol Stent Bests Angioplasty for Popliteal Artery Disease

Role of DCB in SFA Intervention: Predictions Five Years into the Future

Nitinol Stent Performs Better Than Balloon Angioplasty Alone in Treating Lesions of the Popliteal Artery

A Prospective, Randomized Trial of Nitinol Stents vs. Balloon Angioplasty in Obstructive Popliteal Lesions

Debate III. Is Long-term Patency Following Tibial Intervention for Critical Limb Ischemia Necessary? Pro!

After CTO Recanalization, What Is the Role of Drug-Eluting Devices, Covered Stents, Etc?

Expanding the Borders: Endovascular Intervention for Common Femoral and Popliteal Disease

Medtronic Completes Enrollment in Landmark Study of IN.PACT Drug-Eluting Balloon in Peripheral Artery Disease

One year clinical outcomes of MISAGO2 the large multicentre study with Misago the new self-expanding nitinol peripheral stent - final results

Bayer HealthCare's Cotavance Drug Eluting Balloon With Paccocath Technology Reduced Five-Year Target Lesion Revascularization Rates

Bayer HealthCare's MEDRAD Interventional Business Announces Five-Year Data of Cotavance® Drug Eluting Balloon with Paccocath® Technology to be Presented at 2011 TCT

The PROTEUS™ Device Combines Balloon Angioplasty and Embolic Capture of Particles

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content